This study investigates pancreatic ductal adenocarcinoma. It focuses on validating a prognostic score called the HELPP score, which is designed to predict patient outcomes before treatment begins.
The study evaluates the effectiveness of the HELPP score in predicting survival and recurrence patterns in patients. It seeks to understand how well the score can forecast outcomes using routine preoperative data.
- Who can participate: Adults 18 years and older with localized non-metastatic pancreatic ductal adenocarcinoma who can undergo surgery or palliative therapy may join. Informed consent is required.
- Study details: Participants will be observed to validate the HELPP score's predictions. The score uses routine lab tests and other data to estimate outcomes. A placebo is not involved in this observational study.
- Study timelines: The study will last 12 months.
How understandable was the trial content above?
Hard to understand
Easy to understand